ArticleInternational journal of hematology2026
Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The impact of resolved hepatitis B virus (HBV) infection, defined as pretreatment hepatitis B surface antigen (HBsAg) negativity with antibody to hepatitis B core antigen (anti-HBc) positivity, on the clinical characteristics and outcomes of diffuse large B-cell lymphoma (DLBCL) remains unclear. JCOG0601 was a randomized phase II/III trial showing no improvement in progression-free survival (PFS) with dose-dense rituximab plus CHOP in previously untreated DLBCL. This supplementary analysis of JCOG0601 evaluated whether baseline anti-HBc positivity affects PFS and overall survival (OS) in patients with HBsAg-negative DLBCL treated with rituximab-containing CHOP-based therapy. Among 406 eligible patients randomly assigned in JCOG0601, 405 with available baseline HBV serologic data were included. Baseline characteristics and outcomes were compared according to anti-HBc status. Of the 405 patients, 87 were anti-HBc-positive and 318 were anti-HBc-negative. Anti-HBc-positive patients were older than anti-HBc-negative patients (median age, 63 vs. 61 years; p = 0.008). No significant differences in PFS or OS were observed between the two groups (3-year PFS, 78% vs. 81%; 3-year OS, 90% vs. 90%). HBV reactivation occurred in five anti-HBc-positive patients. Baseline anti-HBc positivity was more common in older patients but was not associated with inferior outcomes in HBsAg-negative DLBCL treated with rituximab-containing CHOP-based therapy.Clinical trial registration: JCOG0601 was registered in the Japan Registry of Clinical Trials (jRCTs031180139, date of registration; February 20, 2019).
Indexed as
Identifiers
42801438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.